Zilovertamab Vedotin Plus R-CHP Yields 97.2% CR Rate in DLBCL.
- Published in:
- OncologyLive, 2025, v. 26, n. 1, p. 68
- By:
- Publication type:
- Article
Works matching IS 23745347 AND DT 2025 AND VI 26 AND IP 1
Results: 20
1
2
Daratumumab Significantly Improves PFS and Extends OS in High-Risk Smoldering Myeloma.
- Published in:
- OncologyLive, 2025, v. 26, n. 1, p. 67
- By:
- Publication type:
- Article
3
Fixed-Duration Acalabrutinib/Venetoclax Combo Improves PFS in Frontline CLL.
- Published in:
- OncologyLive, 2025, v. 26, n. 1, p. 61
- By:
- Publication type:
- Article
4
Belantamab Mafodotin Combo Could Be New SOC for Relapsed/Refractory Multiple Myeloma.
- Published in:
- OncologyLive, 2025, v. 26, n. 1, p. 58
- By:
- Publication type:
- Article
5
Biomarker-Guided Treatment Approaches Transform Lung and GI Cancer Management.
- Published in:
- OncologyLive, 2025, v. 26, n. 1, p. 48
- By:
- Publication type:
- Article
6
AI Chatbot Shows Promise in Polypharmacy Management.
- Published in:
- OncologyLive, 2025, v. 26, n. 1, p. 46
- By:
- Publication type:
- Article
7
AI-Enabled Chatbot Replicates Efficacy of SOC Approaches in Aiding Receipt of Cancer Genetic Testing.
- Published in:
- OncologyLive, 2025, v. 26, n. 1, p. 45
- By:
- Publication type:
- Article
8
TRANSFORMING CANCER CARE THROUGH DATA: How Texas Colon & Rectal Specialists Enhances Outcomes, Experiences, and Efficiency.
- Published in:
- OncologyLive, 2025, v. 26, n. 1, p. 42
- By:
- Publication type:
- Article
9
ROSELLA Trial of Relacorilant Targets Stress Response to Overcome Chemoresistance in Ovarian Cancer.
- Published in:
- OncologyLive, 2025, v. 26, n. 1, p. 36
- By:
- Publication type:
- Article
10
CLDN6-Directed Agents Generate Encouraging Early Activity in Solid Tumors.
- Published in:
- OncologyLive, 2025, v. 26, n. 1, p. 33
- By:
- Publication type:
- Article
11
A Road Map for Change Report Provides a Guide to Elevate Breast Cancer Care.
- Published in:
- OncologyLive, 2025, v. 26, n. 1, p. 26
- By:
- Publication type:
- Article
12
Quadruplet Regimens Stand Strong in Newly Diagnosed Multiple Myeloma.
- Published in:
- OncologyLive, 2025, v. 26, n. 1, p. 21
- By:
- Publication type:
- Article
13
Obe-Cel Stands Alone as FDA-Approved CAR T Product With Split Dose Option in ALL.
- Published in:
- 2025
- By:
- Publication type:
- Interview
14
Perioperative Nivolumab Plus Chemotherapy Represents Future of Personalized NSCLC Care.
- Published in:
- OncologyLive, 2025, v. 26, n. 1, p. 10
- By:
- Publication type:
- Article
15
Zanidatamab Gets Go-Ahead for Previously Treated, Unresectable or Metastatic HER2+ Biliary Tract Cancer.
- Published in:
- OncologyLive, 2025, v. 26, n. 1, p. 8
- Publication type:
- Article
16
Nilotinib Tablets Without Mealtime Restrictions Gain Approval in CML.
- Published in:
- OncologyLive, 2025, v. 26, n. 1, p. 8
- Publication type:
- Article
17
Asciminib Receives Green Light for Newly Diagnosed Ph+ Chronic-Phase CML.
- Published in:
- OncologyLive, 2025, v. 26, n. 1, p. 8
- Publication type:
- Article
18
FDA Expands Approval of Methotrexate to Include Pediatric ALL.
- Published in:
- OncologyLive, 2025, v. 26, n. 1, p. 8
- Publication type:
- Article
19
Unique Questions Associated With the Increasing Prominence of Precision/Genomic Medicine in Routine Cancer Care.
- Published in:
- OncologyLive, 2025, v. 26, n. 1, p. 6
- By:
- Publication type:
- Article
20
Notable Oncology Advancements Are Coming From Several Directions.
- Published in:
- OncologyLive, 2025, v. 26, n. 1, p. 4
- By:
- Publication type:
- Article